BALAXI PHARMACEUTICALS LIMITED

Ashish Maheswari

Chairman & Managing Director

Amol Mantri

Chief Financial Officer

400 billion

ollective GDP of these countries in Latin America and Africa, already in our visibility is about $400 billion. These countries have been identified basis of the long term potential that they hold for growth

6 billion

al that they hold for growth from the space that we operate in, with aggregate Pharma imports of $6 billion annually. We currently have our own distribution networks reaching deep into Guatemala, El Salvad

50%

omparable and only sequential comparison would be appropriate. Our pharmaceutical revenues are up 50% as we continue to proliferate in the Latin American geog- raphies, apart from a consolation presen

INR 86.40 crore

Balaxi Pharmaceuticals Limited – November 09, 2022 Our revenues for this quarter stood at INR 86.40 crore, delivering 23% growth quarter on quar- ter. This was mainly driven on back of strong volume growt

23%

ls Limited – November 09, 2022 Our revenues for this quarter stood at INR 86.40 crore, delivering 23% growth quarter on quar- ter. This was mainly driven on back of strong volume growth Latin American

INR 14.80 crore

pipeline of products that are scheduled to be launched as per plan. Our Q2 operating EBITDA is INR 14.80 crore has seen a sequential increase of 5.2% despite absorbing higher cost structures in several newly

5.2%

nched as per plan. Our Q2 operating EBITDA is INR 14.80 crore has seen a sequential increase of 5.2% despite absorbing higher cost structures in several newly launched operations in countries that s

17.1%

ies that should scale up to potential over the next few years. Meanwhile, EBITDA margins stood at 17.1% in- creased by 46 basis points compared to the previous quarter. Here, it is pertinent to highli

46 basis point

e up to potential over the next few years. Meanwhile, EBITDA margins stood at 17.1% in- creased by 46 basis points compared to the previous quarter. Here, it is pertinent to highlight the profitability in market

INR 15.50 crore

expansion that would be expected to see higher contribution in future. Profit after Tax stood at INR 15.50 crore which is a 28.5% increase from the previous year same quarter. Earnings per share for the quarter

28.5%

pected to see higher contribution in future. Profit after Tax stood at INR 15.50 crore which is a 28.5% increase from the previous year same quarter. Earnings per share for the quarter was at INR 15.49

INR 15.49

s a 28.5% increase from the previous year same quarter. Earnings per share for the quarter was at INR 15.49. Having said that, we remain positive on our business outlook on the back of 745 product reg- is

“We expect to leverage existing framework to expand presence in more countries in these regions, including Nicaragua, Chile, and Ecuador in Latin America and Central African Republic in the African continent.”

“Meanwhile, we expect Honduras and El Salvador which are currently at a nascent stage to witness encouraging scale up in revenues in the coming quarters.”

“We expect to see further improvements in all these countries on the back of products launched as well as significant pipeline of products that are scheduled to be launched as per plan.”

“During Q2, as discussed earlier, we initiated our manufacturing initiative and supporting the project was our successful issuance of equity shares and warrants aggregating into INR 49.61 crore on a Preferential Basis.”

“Proceeds will be utilized to part finance our planned EU GMP-compliant facility for Oral Solid Dosages and Liquid Injectables.”

“We completed land acquisition previously, a leading construc- tion has been appointed for project execution and the ground breaking ceremony is scheduled on December 12th of this year.”

“And did you said 2024 we will be commissioning the unit.”

“What is the peak revenue we can expect from this plant?”

“So what I would like to mention here is that this plant is firstly a backward integration project, and secondly this plant will open up new markets for us after we get the EU-GMP approval.”

“Let’s say six months after we operationalize this plant, we hope to get the EU-GMP approval, and once we get the EUGMP approvals there will be many more markets that should open up for us in Southeast Asia, in Central African and in Latin America also.”

Ashish Maheshwari

8

Moderator

5

Yogesh Tiwari

4

Faisal Hawa

2

Ashish Maheshwari

Good evening everyone. A very warm, welcome to Balaxi Pharmaceuticals Limited’s earnings conference call for the second quarter ended September 30th 2022. Our Investor presentation is already uploaded on the stock exchanges and our website for your reference, I'll take you through some of the key highlights of our business and the recent performance parameters. Subsequently, we look forward to an interactive session with all of you to take the conversation forward and give you a deep perspective of our outlook on the business. From the standpoint of the frontier markets that we address here at Balaxi Pharmaceuticals Ltd, on an aggregate, the collective GDP of these countries in Latin America and Africa, already in our visibility is about $400 billion. These countries have been identified basis of the long term potential that they hold for growth from the space that we operate in, with aggregate Pharma imports of $6 billion annually. We currently have our own distribution networks reach